Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDT vs XBI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XBI Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–5 Matrix Metrics)

XBI Overall Winner 6-Pillar Tally: CDT 2 – 2 XBI (2 Tie) Matrix Metrics: CDT 5 – 3 XBI

As of Nov 20, 2026, SPDR S&P Biotech ETF (XBI) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas XBI carries 52.9/100 (HOLD) at $140.18 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile XBI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDT vs XBI
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40
XBI NYSE Arca Head-to-Head Winner
SPDR S&P Biotech ETF
Institutional Equity
$140.18
-2.73% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.17β · 38% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 23.0 Fund 51.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.9%), weak momentum, RSI 35
RSI-14: 35.5 · SMA20: $151.69 · SMA50: $152.71

6-Pillar Scorecard Institutional Category Breakdown (CDT 2 – 2 XBI)

Columns: Metric · CDT · XBI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CDT
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $507,528 N/A
3. Profitability & Quality CDT
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -69.7% N/A
4. Balance Sheet & Cash Flow XBI
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $435,000 Net Debt (0.01x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XBI
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 58.6% (17th %ile)
Put/Call OI Skew N/A 1.27x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDT (5) vs XBI (3)
Institutional Metric CDT XBI Criterion Row Edge
Market Capitalization
Scale
$507,528 N/A Larger Scale CDT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth CDT
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin CDT
Net Profit Margin
Profitability
0.0% N/A Higher Margin CDT
Return on Equity (ROE)
Capital Efficiency
-69.7% N/A Higher ROE CDT
52-Week Range Position
Momentum
2% ($0–$11) 47% ($113–$170) Stronger Trend XBI
Beta / 30D Volatility
Risk Regime
-17.75β · 10175% Vol 1.17β · 38% Vol Lower Realized Risk XBI
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 52.9 / 100 (HOLD) Higher Composite XBI
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($435,000 Net Debt (0.01x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +84.35 pp
CDT: +76.79% · XBI: -7.56%
3M Horizon XBI +76.15 pp
CDT: -90.76% · XBI: -14.61%
6M Horizon XBI +84.57 pp
CDT: -78.1% · XBI: +6.47%
1Y Horizon XBI +109.21 pp
CDT: -86.78% · XBI: +22.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs XBI. Trailing 12-month operating profitability (CDT 0.0% vs XBI N/A) and valuation multiples (CDT N/M vs XBI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M
XBI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XBI CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 58.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact XBI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $145.88 · IV 33.9%

XBI Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($14,588)

Compare $14,588 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 33.9% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $145 / $155 Bull Call Spread

Buy 1x $145C · Sell 1x $155C · 32d

Net Entry $478 Debit
T+5d @ +5% Move +$174 (+36%)
Max Risk / Buffer $478 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $140 / $130 Bull Put Spread

Sell 1x $140P · Buy 1x $130P · 32d

Net Entry $232 Credit
Max Credit / Yield +$232 (+30.2% RoM)
Max Risk / Buffer -5.6% Cushion ($768 Mgn)
5d Edge & Liquidity 69% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Asymmetric 1x1x1 ($150C + $146/$135P)

+1x 11d $146P · -1x 38d $135P · +1x 32d $150C

Net Entry $510 Debit
T+5d @ +5% Move +$213 (+8.4% RoM)
Max Risk / Buffer -7.5% Put Cushion ($2,540 Mgn)
5d Edge & Liquidity Hedged @ -6% (+$90) · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XBI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDT vs XBI Key Questions & Quantitative Answers

As of Nov 20, 2026, SPDR S&P Biotech ETF (XBI) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas XBI carries 52.9/100 (HOLD) at $140.18 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile XBI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDT leads the Growth & Scale pillar: CDT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with XBI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CDT generates N/A in USD-normalized revenue versus N/A for XBI. In operating R&D and SG&A reinvestment, CDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBI.

CDT and XBI trade at balanced relative valuation multiples. CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XBI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDT (-69.7% ROE) versus XBI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk). By comparison, XBI carries 58.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.17β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.